Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection

Journal of Hepatology

Volumn 49, Issue 3, 2008, Pages 339-345

  Halangk, Juliane ^a   Sarrazin, Christoph ^b   Neumann, Konrad ^a   Puhl, Gero ^a   Mueller, Tobias ^a   Teuber, Gerlinde ^b   Klinker, Hartwig ^c   Hinrichsen, Holger ^d   Buggisch, Peter ^e   Landt, Olfert ^f   Weich, Viola ^a   Bergk, Alexandra ^a   Wiedenmann, Bertram ^a   Neuhaus, Peter ^a   Berg, Thomas ^a   Witt, Heiko ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Gemeinschaftspraxis für Innere Medizin   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f TIB MOLBIOL   (Germany)

Author keywords

APRI score; Cirrhosis; Liver biopsy; Liver transplantation; Viral hepatitis

Indexed keywords

COMPLEMENT COMPONENT C5;

ADULT; AGED; ALLELE; ARTICLE; CHI SQUARE TEST; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COMPLEMENT C5; EUROPE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERMANY; HAPLOTYPES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 48449105281     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.05.021     Document Type: Article

References (32)

1. Cohen J. The scientific challenge of hepatitis C. Science 285 (1999) 26-30
2. Feld J.J., and Liang T.J. Hepatitis C - identifying patients with progressive liver injury. Hepatology 43 (2006) 194-206
3. Niederau C., Lange S., Heintges T., Erhardt A., Buschkamp M., Hurter D., et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28 (1998) 1687-1695
4. Wiese M., Grungreiff K., Guthoff W., Lafrenz M., Oesen U., and Porst H. East German Hepatitis C Study Group. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany - a 25-year multicenter study. J Hepatol 43 (2005) 590-598
5. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
6. Poynard T., Mathurin P., Lai C.L., Guyader D., Poupon R., Tainturier M.H., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 (2003) 257-265
7. Ryder S.D., Irving W.L., Jones D.A., Neal K.R., and Underwood J.C. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53 (2004) 451-455
8. Collier J.D., Woodall T., Wight D.G., Shore S., Gimson A.E., and Alexander G.J. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepat 12 (2005) 74-80
9. Bataller R., North K.E., and Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37 (2003) 493-503
10. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125 (2003) 1085-1093
11. Hellier S., Frodsham A.J., Hennig B.J., Klenerman P., Knapp S., Ramaley P., et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38 (2003) 1468-1476
12. Knapp S., Hennig B.J., Frodsham A.J., Zhang L., Hellier S., Wright M., et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 55 (2003) 269-362
13. Smith B.C., Gorve J., Guzail M.A., Day C.P., Daly A.K., Burt A.D., et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27 (1998) 1695-1699
14. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31 (2000) 828-833
15. Sonzogni L., Silvestri L., De Silvestri A., Gritti C., Foti L., Zavaglia C., et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 36 (2002) 195-201
16. Wozniak M.A., Itzhaki R.F., Faragher E.B., James M.W., Ryder S.D., and Irving W.L. Trent HCV Study Group. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 36 (2002) 456-463
17. Glas J., Torok H.P., Tonenchi L., Schiemann U., and Folwaczny C. The -2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology 126 (2004) 1930-1931
18. Bonkovsky H.L., and Salek J. No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C. Gastroenterology 129 (2005) 1361-1362
19. Thorburn D., Curry G., Spooner R., Spence E., Oien K., Halls D., et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 50 (2002) 248-252
20. Hillebrandt S., Wasmuth H.E., Weiskirchen R., Hellerbrand C., Keppeler H., Werth A., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37 (2005) 835-843
21. Walport M.J. Complement. Second of two parts. N Engl J Med 344 (2001) 1140-1144
22. Schieferdecker H.L., Schlaf G., Jungermann K., and Gotze O. Functions of anaphylatoxin C5a in rat liver: direct and indirect actions on nonparenchymal and parenchymal cells. Int Immunopharmacol 1 (2001) 469-481
23. Czermak B.J., Lentsch A.B., Bless N.M., Schmal H., Friedl H.P., and Ward P.A. Role of complement in in vitro and in vivo lung inflammatory reactions. J Leukoc Biol 64 (1998) 40-48
24. Sheerin N.S., and Sacks S.H. Leaked protein and interstitial damage in the kidney: is complement the missing link?. Clin Exp Immunol 130 (2002) 1-3
25. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372-374
26. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
27. Berg T., Sarrazin C., Hinrichsen H., Buggisch P., Gerlach T., Zachoval R., et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology 39 (2004) 1456-1457
28. Lackner C., Struber G., Liegl B., Leibl S., Ofner P., Bankuti C., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 41 (2005) 1376-1382
29. Lok A.S., Ghany M.G., Goodman Z.D., Wright E.C., Everson G.T., Sterling R.K., et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 42 (2005) 282-292
30. Stickel F., and Osterreicher C.H. The role of genetic polymorphisms in alcoholic liver disease. Alcohol Alcohol 41 (2006) 209-224
31. Thursz M. Pros and cons of genetic association studies in hepatitis B. Hepatology 40 (2004) 284-286
32. Donaldson P.T. Genetics of autoimmune and viral liver diseases; understanding the issues. J Hepatol 41 (2004) 327-332